Syncom Formulation (India) (NSE:SYNCOMF) 3-Year EBITDA Growth Rate : 12.20% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) 3-Year EBITDA Growth Rate?

Syncom Formulation (India)'s EBITDA per Share for the three months ended in Dec. 2023 was ₹0.15.

During the past 12 months, Syncom Formulation (India)'s average EBITDA Per Share Growth Rate was 43.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 12.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 15.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Syncom Formulation (India) was 94.70% per year. The lowest was -51.90% per year. And the median was -0.10% per year.

Competitive Comparison of Syncom Formulation (India)'s 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syncom Formulation (India)'s 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s 3-Year EBITDA Growth Rate falls into.

Syncom Formulation (India) 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Syncom Formulation (India) (NSE:SYNCOMF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Syncom Formulation (India) 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines